gavel and capitol building banning 7-OH

The 7-OH Ban Explained: Timeline, Schedule I Rules & What Happens Next

Written by: Matthew von Boecklin

|

Published on

On August 5 th, 2026, the United States is expected to temporarily ban 7-hydroxymitragynine (7-OH) and several synthetic derivatives: mitragynine pseudoindoxyl (MP), MGM-15, and MGM-16. The ban comes from a coordinated effort of the Department of Health and Human Services (HHS), Drug Enforcement Agency (DEA) and Food and Drug Administration (FDA), in an effort to prevent a new drug epidemic. Under the Controlled Substances Act (CSA), 7-OH will be classified as a Schedule I substance, the most restrictive category in American drug law. When the ban takes effect, possession, sale, and manufacture of 7-OH and its banned derivatives instantly become illegal for general commercial sale and personal possession.


Temporary bans are different than full, permanent bans in that the period of prohibition in possession, sale, and manufacture within the US lasts two years, with an option to extend for another year. Temporary bans are a means for the US government to shield citizens from substances that pose an “imminent hazard to public safety.” During the prohibition period, formal administrative and interagency hearings are conducted to produce enough evidence for permanent scheduling of a substance. This process, which can involve medical research and lengthy reviews, may take years to complete.

Why 7-OH is Being Banned

Rising Public Health Concerns

Though 7-OH products have been sold under the “dietary supplement” designation, which exempts them from FDA approval, the National Poison Data System has reported record levels of toxic 7-OH exposure in the US, including both nonfatal and fatal overdosing.


Between January 2023 and April 2026, Emergency Medical Services across 841 US counties reported 3,672 suspected non-fatal overdoses of 7-OH, mitragynine, and high-potency kratom products.


Between 2015-2025, poison centers saw a 1,200% surge in annual calls to poison centers regarding kratom and 7-OH, with an exponential spike in calls occurring in 2025. The Center for Disease Control (CDC) attributes this spike to the rapid emergence of high-potency, semi-synthetic 7-OH products in gas stations, smoke shops, and e-commerce stores.


In the same period, the CDC documents 233 deaths associated with kratom and 7-OH products. Though 7-OH toxicity can trigger fatal respiratory depression, similar to the effects of overdosing on full opioid agonists such as heroin and fentanyl, the overwhelming majority of these fatalities involves polysubstance combination, such as alcohol, opioids, or benzodiazepines.

Criteria for Scheduling

7-OH and its derivatives MP, MGM-15, and MGM-16 will become Schedule I of the CSA substances on August 5 th, 2026. Three factors contribute to the Schedule I status:

  • 1. High potential for abuse: 7-OH and its synthetic derivatives carry a high risk for abuse, including physical and psychological dependence, due to their strong binding affinity to opioid receptors in the nervous system.
  • 2. No currently accepted medical use: According to the FDA and DEA, there is no established, peer-reviewed medical application in treatment within the United States for 7-OH products.
  • 3. Lack of accepted safety: Standardized, accepted safety protocol for 7-OH products do not exist. According to the DEA and HHS, these products cannot be used safely, even under formal supervision.

Beyond this, government regulators are taking aim at the kratom industry’s efforts to chemically manipulate the psychoactive ingredients in the natural kratom leaf to synthesize high-potency 7-OH products. Plain leaf kratom contains trace levels of 7-OH, typically 0.02% by dry weight. Mitragynine, the other psychoactive ingredient in the kratom leaf, is much more abundant in comparison.


To synthesize mitragynine to 7-OH, chemical oxidation process are used to create concentrated 7-OH products. These concentrations can contain tens of milligrams of isolated 7-OH per unit, far above the legal limit for the 7-OH molecule: 1 milligram, or 0.05% concentration by weight. Regulators points to this chemical manipulation as an attempt by the kratom industry to engineer products akin to synthetic opioids.


Schedule I is the most restrictive category under the CSA because these substances have no currently accepted medical use in the U.S. and cannot be prescribed by doctors. By contrast, highly addictive opioids like oxycodone, morphine, and fentanyl are classified as Schedule II because they have recognized medical applications and can be prescribed under strict supervision.

Enforcement and Consequences

Enforcement of the federal 7-OH temporary Schedule I ban will operate across four main levels, targeting every stage of the supply chain rather than focusing strictly on individual consumers:

  1. Supply Chain & Manufacturing (DEA & DOJ): Once the temporary order is active, domestic production, chemical transformation (such as oxidizing mitragynine into 7-OH), and commercial distribution become federal felonies. Federal law enforcement can seize physical facilities, laboratory equipment, commercial inventory, and financial assets through civil and criminal forfeiture.
  2. Importation & Borders (CBP & FDA): Customs and Border Protection works with FDA inspectors at ports of entry to intercept bulk chemical imports, raw extracts, and finished products exceeding the 0.05% / 1 mg concentration threshold. The FDA uses Import Alerts to automatically detain mislabeled overseas shipments (often declared as "botanical extracts" or "cleaning supplies").
  3. Retail & Smoke Shop Compliance (State & Local Authorities): Physical retail outlets, including gas stations, smoke shops, and convenience stores, will face routine inspections from state health departments and local law enforcement. Non-compliant retailers risk product confiscation, civil fines, and the revocation of state business or tobacco licenses. In many states, local law enforcement can charge retailers under state-controlled substance laws that automatically adopt federal Schedule I listings.
  4. E-Commerce & Financial Infrastructure: Online vendors will face domain seizures and payment gateway blacklisting. Major credit card networks (Visa, Mastercard) and merchant banks strictly prohibit processing payment transactions for Schedule I controlled substances, effectively severing their merchant accounts and payment processing abilities.

For individual consumers, many of whom are physically and/or psychologically dependent on the substance, the 7-OH ban abruptly shifts the substance from being readily available over the counter to a strictly illegal, controlled substance. Once 7-OH is scheduled, possession of high-concentration 7-OH greater than 0.05% by weight or over 1 milligram per product) becomes a federal crime. State-level laws may automatically update their controlled substance lists to match federal lists, thus adopting the federal law, typically within 30-60 days. The immediate consequence is that both federal agents and state police can charge 7-OH consumers with misdemeanor or felony possession.


Should individual consumers seek 7-OH products illegally, they face new hazards in protection outside of law enforcement. In legal markets, kratom and 7-OH manufacturers are required to obtain and keep 3 rd-party laboratory tests called Certificates of Analysis (COAs) that confirm chemical concentrations in the 7-OH product. These chemicals range from the 7-OH and mitragynine molecules to heavy metals and known toxins/ carcinogens. Without the need for a COA, consumers of illegally-manufactured 7-OH products may endanger their health beyond the risks of addiction and dependence. 


Additionally, illegal substances typically operate on black-market pricing, which can skyrocket the normal price of 7-OH products. For those consumers already physically and psychologically dependent on 7-OH, these elevated prices may put new, extreme financial pressure on maintaining access to the substance.

The Rise of and Reaction to 7-OH

From 2015-2019, the US kratom industry was estimated at $500 million to $1 billion, annually. Between 2020-2023, this valuation jumped to between $1.5 billion and $2 billion, and by 2026, was estimated between $2.2 billion to $2.56 billion. In 2020, the industry shifted from primarily plain leaf kratom to concentrated shots, liquids, and extracts. In 2024, the industry shifted again to include production of hyper-concentrated 7-OH products.


It is estimated that from 2024-2026, consumers purchased over 2 billion individual 7-OH servings across the US. 7-OH products, which typically retail for between $15-$35 for 2-5 tablet packs, carry high profit margins. For gas stations and smoke shops, 7-OH products became quick and consistent revenue drivers. This represents a massive shift from the near-zero market presence 7-OH products had at the start of 2024. Today, hundreds of distinct 7-OH product lines exist.


The American Kratom Association (AKA) and the Natural Products Association (NPA), both pro-kratom organizations, have actively lobbied public agencies to ban 7-OH products. The AKA has lobbied congress, state legislatures, and federal agencies to treat 7-OH products as distinct from traditional kratom products, such as plain leaf kratom. The AKA has referred to 7-OH as an “adulterated, chemically manipulated synthetic opioid.”


The American Medical Association (AMA), updated its official policy to specifically target 7-OH products, calling for a complete ban on the sales, distribution, and marketing of 7-OH products. The American Poison Control Centers (AAPCC) has provided both local and national 7-OH exposure data to the HHS and DEA, framing 7-OH products as an emerging public health hazard requiring emergency intervention.


State-level action has already occurred to ban kratom, 7-OH, or both. The table below provides an overview of state-by-state legal status for kratom and 7-OH.


Regulatory Category

States

What Is Allowed?

Legal & Criminal Penalties

Full Prohibition


(Total Ban)

• Alabama


• Arkansas


• Connecticut


• Indiana


• Kansas


• Louisiana


• Tennessee


• Vermont


• Wisconsin

Nothing. All kratom leaf, extracts, and 7-OH products are classified as controlled substances or illegal analogs.

Criminal Offense. Possession ranges from misdemeanor to felony; manufacturing and sale are major felonies subject to asset seizure.

Targeted 7-OH Bans


(Hybrid Model)

• Florida


• Ohio


• Virginia


• Colorado


• South Carolina

Natural leaf kratom only. Concentrated 7-OH tablets, shots, and synthetic derivatives are explicitly banned.

Dual Track. Raw leaf is legally sold to adults (21+); commercial possession or retail sale of high-potency 7-OH carries controlled substance charges.

KCPA Regulated


(Kratom Protection Acts)

Over 30 states, including:


• Arizona, Georgia, Mississippi, Nevada, Oklahoma, Oregon, Texas, Utah, West Virginia

Natural leaf & regulated extracts. Products must contain <1% to 2% 7-OH of total alkaloid content.

Civil & Regulatory. Retailers violating age limits (21+), alkaloid caps, or COA lab-testing rules face civil fines and license revocations.

Local Municipal Bans


(Patchwork Cities/Counties)

Specific jurisdictions in otherwise legal states:


• San Diego, CA


• Denver, CO


• Sarasota County, FL


• 30+ MS municipalities

Varies by city/county code. Often bans human consumption or retail sales within municipal limits.

Local Enforcement. Violations carry local misdemeanor charges, municipal fines, or police product confiscation.

Where We Go From Here

The imminent August 5, 2026 emergency ban marks a major turning point for public health and the kratom retail landscape. Over the next 24 to 36 months of this temporary scheduling period, federal researchers and health officials will conduct formal reviews to determine if 7-OH transitions into a permanent Schedule I substance. In the meantime, the immediate burden falls heavily on regular consumers who face sudden supply disruption, as well as retail businesses adjusting to rapid inventory shifts.


If you or someone you know uses high-dose 7-OH products, navigating abrupt discontinuation safely is critical. Healthcare professionals strongly advise against turning to unverified black-market alternatives, which lack basic safety testing and carry significant risks of dangerous adulteration. Instead, consulting a medical professional or exploring accredited clinical support options remains the safest path forward during this regulatory transition.


If you or someone you know will be affected by this ban, here is a list of confidential support resources, national hotlines, harm reduction networks, and online peer communities.


Medical & Substance Support Hotlines

  • SAMHSA’s National Helpline (Substance Abuse and Mental Health Services Administration)
    • Phone:1-800-662-4357 (HELP) | TTY: 1-800-487-4889
    • Details: Free, confidential, 24/7/365 treatment referral and information service (available in English and Spanish). It provides local referrals to medical detox facilities, outpatient clinics, Medication-Assisted Treatment (MAT) providers, and support groups.
  • 988 Suicide & Crisis Lifeline
    • Phone / Text:988
    • Details: Free, confidential, 24/7 crisis support for anyone experiencing intense emotional distress, severe panic, acute withdrawal anxiety, or thoughts of self-harm.
  • National Poison Control Center
    • Phone:1-800-222-1222
    • Details: Connects callers directly to local medical experts for immediate, free advice if someone experiences adverse reactions or accidental toxicity from high-potency extracts.


Harm Reduction & Safety Services

  • Never Use Alone
    • Phone:1-800-484-3731 or 1-877-696-1996
    • Details: A nationwide, non-judgmental overdose prevention line run by volunteers with lived experience. If an individual is taking substances alone during a transition period, an operator stays on the line and alerts emergency medical services (EMS) only if the caller becomes unresponsive.
  • NEXT Distro
    • Website: nextdistro.org
    • Details: An online harm reduction organization that provides free mail-based naloxone (Narcan) and harm-reduction resources to individuals who do not have easy local access.


Online Peer Support Communities

  • Kratom Quitters
    • Website: kratomquitters.com
    • Details: Kratom Quitters hosts three meetings a day, every day, for those seeking support related to kratom and 7-OH use. The mission of Kratom Quitters is to raise awareness, provide support, and offer resources to individuals and their loved ones affected by kratom addiction.
  • r/quittingkratom (Reddit Community)
    • Details: One of the largest active online support communities dedicated to helping individuals tapering down or discontinuing raw kratom and high-potency extracts like 7-OH. Features user-created tapering guides, withdrawal symptom management discussions, and daily accountability threads.
  • r/kratom (Reddit Community)
    • Details: A broad community focused on discussion surrounding botanical kratom, regulatory news, advocacy updates, and state-by-state legal changes.
  • In-Person Peer Support Groups:
    • SMART Recovery (smartrecovery.org): Science-based, self-empowered addiction recovery support groups (both in-person and online).
    • Narcotics Anonymous (na.org): 12-step peer support groups nationwide for those navigating physical or psychological substance dependence.

Sources and Further Reading

1. Federal Regulatory & Legal Actions

  • U.S. Drug Enforcement Administration (DEA) & Federal Register:

    • DEA Docket No. DEA-1570: Schedules of Controlled Substances: Temporary Placement of 7-Hydroxymitragynine and Synthetic Analogues into Schedule I. Federal Register Notice of Intent (July 2026).
    • Controlled Substances Act (CSA), Title 21 United States Code (21 U.S.C. § 811(h) – Emergency Temporary Scheduling Authority; 21 U.S.C. § 812 – Schedules of Controlled Substances; 21 U.S.C. § 844 – Penalties for Simple Possession).
    • U.S. FDA: Public Health Advisory and Warnings on 7-Hydroxymitragynine and Unapproved Synthetic Alkaloid Products (2025–2026).
    • HHS Office of the Assistant Secretary for Health (OASH): Scientific and Medical Evaluation of 7-Hydroxymitragynine for Schedule I Control.


2. Epidemiological, Poison Control & Overdose Data

  • Centers for Disease Control and Prevention (CDC):
    • CDC Morbidity and Mortality Weekly Report (MMWR): Kratom-Related Exposure Calls and Hospitalizations Reported to U.S. Poison Centers (2015–2025).
    • CDC State Unintentional Drug Overdose Reporting System (SUDORS): Overdose Fatalities Involving Kratom Alkaloids and Polysubstance Co-Ingestion.
  • National Poison Data System (NPDS) & NDEWS:
    • American Association of Poison Control Centers (AAPCC): Annual NPDS Exposure Reports on Kratom and Concentrated Alkaloids.
    • National Drug Early Warning System (NDEWS): Emergency Medical Services (EMS) Encounter Data for Suspected Non-Fatal Overdoses Involving High-Potency Botanical Extracts.


3. Industry & Economic Market Data

  • Market Research & Retail Analytics:
    • SPINS / IRI Retail Tracking Data: Botanical Supplement & Convenience Channel Market Reports (2020–2026).
    • Grand View Research & SPINS Data: U.S. Kratom and Botanical Extract Market Size, Share & Trend Analysis.
    • American Kratom Association (AKA): Economic Impact Analysis of the U.S. Kratom Industry and Product Manufacturing Estimates.


4. Lobbying & Stakeholder Positions

  • American Kratom Association (AKA):
    • AKA Regulatory Statements & Legislative Filings: Differentiating Whole-Leaf Mitragyna Speciosa from Synthetic 7-Hydroxymitragynine Analogs.
  • American Medical Association (AMA):
    • AMA House of Delegates Resolutions: Policy H-95.922 – Public Health Controls and Warnings for High-Potency Alkaloid Extracts.
  • Natural Products Association (NPA):
    • NPA Policy Briefs: Dietary Supplement Health and Education Act (DSHEA) Compliance and Adulteration Standards for Concentrated Botanical Extracts.


5. State Laws & Municipal Codes

  • State Controlled Substance Statutes & KCPA Frameworks:
    • Total Ban States: Code of Alabama § 20-2-23; Arkansas State Board of Pharmacy Schedule I Listings; Louisiana Act 41 (2025); Tennessee Code Annotated § 39-17-452 ("Matthew Davenport's Law").
    • Targeted/Hybrid States: Florida Department of Health Emergency Rule on 7-OH; Ohio State Board of Pharmacy Emergency Rules.
    • KCPA States: Utah Code § 4-45 (Kratom Consumer Protection Act); Oregon Revised Statutes § 475.935; Texas Health & Safety Code Chapter 444.


6. Support & Harm Reduction Resources
← Go back